Health
First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC – News-Medical.Net
Oncotarget Volume 11, Issue 34 features Figure 1, “BRAF inhibitor-induced changes in cell viability,” by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprisin…
Oncotarget Volume 11, Issue 34 features Figure 1, “BRAF inhibitor-induced changes in cell viability,” by Pickles, et al. which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.
Resistance to BRAF inhibition in CRC arises in part through the generation and activation of RAF dimers resulting in MEK-ERK pathway reactivation.
The Oncota…
-
Noosa News23 hours agoEmerald house fire victims identified amid police probe
-
General20 hours agoQueensland considers allowing dingoes to be kept as pets
-
General22 hours agoCoolangatta QCWA branch rejects $10 million offer for humble hall
-
Noosa News22 hours agoBrisbane news live: Cemetery catches fire in Brisbane’s east